Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

01 April 2005 : Original article  

Eradication rate of Helicobacter pylori in dyspeptic patients.

Mohsen Amini, Hossein Khedmat, Fatemeh Yari

Med Sci Monit 2005; 11(4): CR193-195 :: ID: 15883

Abstract

BACKGROUND: The eradication of Helicobacter pylori (HP) is dependent on several bacteriologic and geographic variables. Multiple-drug regimens have been tried in order to eradicate HPi; however, the optimal drug has not yet been found. MATERIAL/METHODS: In this single-blind, randomized clinical trial, 245 dyspeptic patients with positive rapid urease tests or positive cultures for HP were entered in the study and randomly treated with one of 3 drug regimens A, B, or C for 14 days. Each regimen was administered to 76 patients. Regimen A consisted of omeprazole 20 mg bid + bismuth subcitrate 120 mg 2 tab. bid + metronidazole 250 mg 2 tab. bid + tetracycline 250 mg 2 cap. bid. Regimen B consisted of omeprazole 20 mg bid + bismuth subcitrate 120 mg 2 tab. bid + furazolidone 100 mg 2 tab. bid + tetracycline 250 mg 2 cap. bid. Regimen C consisted of omeprazole 20 mg bid + bismuth subcitrate 120 mg 2 tab. bid + ciprofloxacin 500 mg bid. A urea breath test was performed 1-2 months after eradication. RESULTS: Of the 245 patients, 228 completed their treatment course. 57% were male and 43% female. Eradication rates were 76.3%, 68.4%, and 67.1% in groups A, B, and C, respectively (P=0.05). The eradication rate of drug regimen A was greater than B in males (86% vs. 63%; p

Keywords: Ciprofloxacin - therapeutic use, Dyspepsia - microbiology, Organometallic Compounds - therapeutic use, Tetracycline - therapeutic use, Urea - analysis, Analysis of Variance, Anti-Bacterial Agents - therapeutic use, Breath Tests, Ciprofloxacin - therapeutic use, Drug Therapy, Combination - therapeutic use, Dyspepsia - microbiology, Furazolidone - therapeutic use, Helicobacter Infections - therapy, Helicobacter pylori - isolation & purification, Metronidazole - therapeutic use, Omeprazole - therapeutic use, Organometallic Compounds - therapeutic use, Single-Blind Method, Tetracycline - therapeutic use, Urea - analysis

Comments

Editorial

04 June 2022 : Editorial  

Editorial: Acute Hepatitis of Unknown Origin in Children. Is Autoimmunity at Play?

Nahum Mendez-Sanchez, Shreya C. Pal
Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico

DOI: 10.12659/MSM.937371

Med Sci Monit 2022; 28:e937371

In Press

23 Jun 2022 : Clinical Research  

A Real-World Study to Compare the Safety and Efficacy of Paritaprevir/Ombitasvir/Ritonavir and Dasabuvir, w...

Med Sci Monit In Press; DOI: 10.12659/MSM.936706  

22 Jun 2022 : Clinical Research  

A Single-Center Study Comparing the Effects of Thoracic Spine Manipulation vs Mobility Exercises in 26 Offi...

Med Sci Monit In Press; DOI: 10.12659/MSM.937316  

21 Jun 2022 : Clinical Research  

Optimal Timing and Outcomes of Minimally Invasive Approach in Acute Biliary Pancreatitis

Med Sci Monit In Press; DOI: 10.12659/MSM.937016  

16 Jun 2022 : Clinical Research  

Renal Manifestations in Inflammatory Bowel Disease: A Cohort Study During the Biologic Era

Med Sci Monit In Press; DOI: 10.12659/MSM.936497  

Most Viewed Current Articles

30 Dec 2021 : Clinical Research  

Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...

DOI :10.12659/MSM.935379

Med Sci Monit 2021; 27:e935379

08 Mar 2022 : Review article  

A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...

DOI :10.12659/MSM.936292

Med Sci Monit 2022; 28:e936292

01 Nov 2020 : Review article  

Long-Term Respiratory and Neurological Sequelae of COVID-19

DOI :10.12659/MSM.928996

Med Sci Monit 2020; 26:e928996

01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750